Porous Calcium Hydroxyapatite
119
THF. The solvent was evaporated under reduced pressure and the residue was
purified by recrystallization in EtOH. The product was analysed by 1H NMR,
13C NMR, IR, and mass spectrometry, and compared to samples cited in
literature.[6a,12]
5-(1,3-benzodioxol-5-ylmethyl)-1,3-diphenyl pyrazoline (3c): Mp
1
114–1168C (EtOH). H NMR (CDCl3): d 3.1 (m, 2H, CH2), 3.4 (m, 2H,
CH2-C ¼ N), 4.2 (m, 1H, CH), 5.8 (s, 2H, OCH2O), 6.7–7.4 (m, 13H,
Harm). 13C NMR (CDCl3): d 37.0 (CH2), 44.3 (CH2-C ¼ N), 64.6 (CH),
101.0 (OCH2O), 108.5–147.7 (Carm), 162.0 (C ¼ N). CIMS (isobutane,
reagent gas): m/z 357 [M þ H]. Anal. calcd. for C23H20N2O2: C, 77.51; H,
5.66; N, 7.86. Found C, 77.45; H, 5.60; N, 7.89.
N-[1,3-diphenyl-pyrazolinyl methyl] saccharin (3d): Mp 110–1128C
1
(EtOH). H NMR (CDCl3): d 3.9 (m, 2H, CH2-C ¼ N), 4.2 (m, 1H, CH-N),
4.5 (m, 2H, CH2-N-SO2), 5.8 (s, 2H, OCH2O), 6.9–8.0 (m, 14H, Harm).
13C NMR (CDCl3): d 36.3 (CH2-N-SO2), 42.7 (CH2-C ¼ N), 63.8 (CH-N),
111.9–148.3 (Carm), 164.8 (C ¼ N), 166.0 (C ¼ O). CIMS (isobutane,
reagent gas): m/z 418 [M þ H]þ. Anal. calcd. for C23H20N2O2: C, 66.17;
H, 4.59; N, 10.07. Found C, 66.48; H, 4.55; N, 10.13.
ACKNOWLEDGMENTS
Financial assistance of Ministry of Education, Government of Morocco
(PROTARS III, D13/57) and CNRST-Morocco are gratefully acknowledged.
REFERENCES
1. (a) Cinquini, M.; Cozzi, F. Methoden der Organische Chemie (Houben-Weyl);
Stereoselective Synthesis., G. Thieme: Stuttgart, 1995; Vol. E 21c, 2953;
(b) Gothelf, K. V.; Jorgensen, K. A. Chem. Rev. 1998, 98, 863; (c) Kunz, H.;
Ru¨ch-Braun, K. Chiral Auxiliaries in Cycloadditions; Wiley-VCH: Weinheim,
¨
1999; (d) Karlsson, S.; Hogberg, E.-H. Org. Prep. Proc. Int. 2001, 33, 1032;
(e) Conti, P.; Roda, G.; Barberis Negra, F. F. Tetrahedron Asym. 2001, 12, 1363.
2. (a) Palaska, E.; Aytemir, M.; Uzbay, T.; Erol, D. Eur. J. Med. Chem. 2001, 36, 539;
(b) Sharma, S.; Srivastava, V. K.; Kumar, A. Eur. J. Med. Chem. 2002, 37, 689;
(c) Tabarelli, Z.; Rubin, M. A.; Berlese, D. B.; Sauzem, P. D.; Missio, T. P.;
Teixeira, M. V.; Sinhorin, A. P.; Martins, M. A.; Zanatta, N.; Bonacorso, H. G.;
Mello, C. F. Braz. J. Med. Biol. Res. 2004, 37, 1531; (d) Rani, P.;
Srivastava, V. K.; Kumar, A. Eur. J. Med. Chem. 2004, 39, 449;
(e) Berghot, M. A.; Moawad, A. B. Eur. J. Pharm. Sc. 2003, 20, 173.
3. (a) Onaka, M.; Ohta, A.; Sugita, K.; Izumi, Y. Appl. Catal. A 1995, 125, 203;
´
´
´
(b) Liptakova, B.; Hronec, M.; Cvengro Ova, Z. Catal. Today 2000, 61, 143;
(c) Maeda, Y.; Washitake, Y.; Nishimura, T.; Iwai, K.; Yamauchi, T.;
Uemura, S. Tetrahedron 2004, 60, 9031; (d) Muzart, J. Tetrahedron 2003, 59,
5789; (e) Hara, T.; Mori, K.; Mizugaki, T.; Ebitani, K.; Kaneda, K. Tetrahedron
Lett. 2003, 44, 6207; (f) Elkabouss, K.; Kacimi, M.; Ziyad, M.; Ammar, S.;